-
Elan Corp. agreed to pay $1 billion for a share of the royalties on new drugs from Theravance Inc. as the Irish drugmaker tries to persuade shareholders to spurn a takeover offer by Royalty Pharma.
-
GlaxoSmithKline Plc and Theravance Inc. won U.S. approval of their once-daily drug Breo Ellipta to treat a lung disorder that is the third-leading cause of death.
-
Theravance Inc.’s projected U.S. approval for its respiratory drugs is fueling speculation of an almost threefold revenue surge and a takeover bid from partner GlaxoSmithKline Plc.
-
Affymax Inc. fell as much as 85 percent after the drugmaker and partner Takeda Pharmaceutical Co. voluntarily recalled an anemia treatment for kidney dialysis patients after reports of three fatal reactions.
-
Genzyme Corp.’s chief executive officer, Henri A. Termeer , will leave his post of 26 years after Sanofi-Aventis SA closes its $20.1 billion purchase of his company. He may not be out of a job for long.
-
Affymax Inc. won U.S. approval for Omontys, a competitor to Amgen Inc.’s anemia treatments that have been the only options for patients with loss of kidney function for more than 20 years.
-
Human Genome Sciences Inc. investors betting on a sweetened bid from GlaxoSmithKline Plc stand to reap a 13 percent return, even as their expectations of securing America’s biggest price increase diminish.
-
Theravance Inc. rose the most in 11 months on investor speculation that GlaxoSmithKline Plc may purchase the remaining 73 percent of the company that it doesn’t already own.
-
Options traders are betting potential acquirers from AstraZeneca Plc to Bristol-Myers Squibb Co. will have to spend 26 percent more than its current price to buy Amylin Pharmaceuticals Inc.
-
Affymax Inc. rose the most in seven months after the biotechnology company and partner Takeda Pharmaceutical Co. agreed to supply their anemia drug Omontys to Fresenius Medical Care AG for use in dialysis patients.
Rate this Page